Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.31 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.31 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.31 |
| ▸ | ITGAV | P06756 | 1/20 | 0.31 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.31 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1005092 | 1.00 | GLS (0.47) | GLSAPEX1KDM4ETSHRHTT | |
| SCHEMBL200462 | 1.00 | GLS (0.47) | GLSAPEX1KDM4ETSHRHTT | |
| Biphenyl SCHEMBL7177377 | 0.89 | GLS (0.41) | GLSAPEX1KDM4ETSHRHTT | |
| SCHEMBL9460988 | 0.86 | GLS (0.46) | GLS | |
| SCHEMBL18218788 | 0.85 | GLS (0.47) | GLSHTTSMN1; SMN2BACE1 | |
| SCHEMBL18914987 | 0.85 | GLS (0.47) | GLSKDM4EBACE1 | |
| SCHEMBL18219056 | 0.85 | GLS (0.47) | GLSHTTSMN1; SMN2BACE1 | |
| SCHEMBL23296774 | 0.83 | GLS (0.46) | GLSBACE1 | |
| SCHEMBL183678 | 0.83 | GLS (0.46) | GLSBACE1 | |
| SCHEMBL2280018 | 0.83 | GLS (0.46) | GLSBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108864148-B | Rapamycin-40-malic acid sodium salt and preparation method and application thereof | 福建省微生物研究所 | 2021-09-03 | — | — | CN | claimed |
| US-20260116913-A1 | NEUROSTEROID COMPOUNDS AND METHODS FOR THEIR PREPARATION AND USE IN TREATING CENTRAL NERVOUS SYSTEM DISORDERS | TEXAS A & M UNIV SYS (US) | 2026-04-30 | — | — | US | disclosed |
| US-12509487-B2 | Neurosteroid compounds and methods for their preparation and use in treating central nervous system disorders | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2025-12-30 | — | — | US | disclosed |
| WO-2025037940-A1 | PYRAZOLE-1-CARBOXAMIDES AS RIP1 KINASE INHIBITORS | BISICHEM CO., LTD. (KR) | 2025-02-20 | — | — | WO | disclosed |
| WO-2023134629-A1 | NUCLEAR TRANSPORT REGULATOR AND USE THEREOF | 上海海雁医药科技有限公司 | 2023-07-20 | — | — | WO | disclosed |
| WO-2023134629-A1 | NUCLEAR TRANSPORT REGULATOR AND USE THEREOF | 上海海雁医药科技有限公司 | 2023-07-20 | — | — | WO | disclosed |
| US-20230151052-A1 | NEUROSTEROID COMPOUNDS AND METHODS FOR THEIR PREPARATION AND USE IN TREATING CENTRAL NERVOUS SYSTEM DISORDERS | THE TEXAS A&M UNIVERSITY SYSTEM | 2023-05-18 | — | — | US | disclosed |
| US-11542296-B2 | Neurosteroid compounds and methods for their preparation and use in treating central nervous system disorders | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2023-01-03 | — | — | US | disclosed |
| CN-108785305-B | Heterocyclic inhibitors of glutaminase | 卡利泰拉生物科技公司 | 2021-10-29 | — | — | CN | disclosed |
| CN-108864148-B | Rapamycin-40-malic acid sodium salt and preparation method and application thereof | 福建省微生物研究所 | 2021-09-03 | — | — | CN | disclosed |
| US-20020143186-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2002-10-03 | — | — | US | disclosed |
| US-6359061-B1 | COMBINATORIAL LIBRARIES ARE USEFUL FOR SCREENING IN BIOLOGCAL ASSAYS IN ORDER TO IDENTIFY PHARMACEUTICALLY USEFUL COMPOUNDS | ISIS PHARMACEUTICALS, INC. | 2002-03-19 | — | — | US | disclosed |
| EP-1183091-A1 | OPTIMIZATION OF LIGAND AFFINITY FOR RNA TARGETS USING MASS SPECTROMETRY | ISIS PHARMACEUTICALS, INC. (US) | 2002-03-06 | — | — | EP | disclosed |
| WO-2002000612-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2002-01-03 | — | — | WO | disclosed |
| US-6316623-B1 | USEFUL FOR SCREENING IN BIOLOGICAL ASSAYS IN ORDER TO IDENTIFY PHARMACEUTICALLY USEFUL COMPOUNDS | ISIS PHARMACEUTICALS, INC. | 2001-11-13 | — | — | US | disclosed |
| WO-2001058573-A1 | OPTIMIZATION OF LIGAND AFFINITY FOR RNA TARGETS USING MASS SPECTROMETRY | ISIS PHARMACEUTICALS, INC. (US) | 2001-08-16 | — | — | WO | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| EP-1082323-A2 | OXAZOLIDINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AstraZeneca UK Limited (GB) | 2001-03-14 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| WO-1999064417-A2 | OXAZOLIDINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151052-A1 | NEUROSTEROID COMPOUNDS AND METHODS FOR THEIR PREPARATION AND USE IN TREATING CENTRAL NERVOUS SYSTEM DISORDERS | CYP11B2, CYP21A2, CYP11B1 | GLS 624/4885APEX1 3945/4885KDM4E 4509/4885 |
| US-12509487-B2 | Neurosteroid compounds and methods for their preparation and use in treating central nervous system disorders | SLC6A11, GABRE, SLC6A13 | GLS 1422/4885APEX1 4847/4885KDM4E 2859/4885 |
| US-20260116913-A1 | NEUROSTEROID COMPOUNDS AND METHODS FOR THEIR PREPARATION AND USE IN TREATING CENTRAL NERVOUS SYSTEM DISORDERS | CHRNA9, HSD3B2, HSD3B1 | GLS 2814/4885APEX1 3944/4885KDM4E 2002/4885 |
| US-11542296-B2 | Neurosteroid compounds and methods for their preparation and use in treating central nervous system disorders | CYP11B2, CYP21A2, CYP11B1 | GLS 624/4885APEX1 3945/4885KDM4E 4509/4885 |
| US-20020143186-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | GLS 236/4885APEX1 3309/4885KDM4E 3671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.